Who Watches The Machines?

Responsible Deployment of Decision Technologies in Healthcare

UNC Health Technology Symposium
November 30th, 2018

Greg Kuhnen
Senior Research Director
kuhneng@advisory.com
1. The Data Dilemma
2. AI and the New Machine Age
3. Who Watches The Machines?
The Rapid Rise of EHRs

Basic EHR Adoption 2008–2015

MU CDS Requirements by Stage

Stage 1
2011–2014
- One CDS rule
- Drug-drug/drug-allergy interaction checking

Stage 2 and Modified Stage 2
2014–2018
- Retain Stage 1 requirements¹
- Increase number of CDS rules to 5

Stage 3
Begins 2019²
- CDS removed as a specific requirement¹; CMS expects functionality enabled regardless


1) CDS removed from Meaningful Use (MU) for Medicare hospitals effective CY 2017; remains a requirement for Medicaid MU program.
2) Stage 3 is optional in 2017 and 2018, and proposed to be required in 2019.

©2018 Advisory Board • All Rights Reserved • advisory.com • 36516D
Pockets of Success with Clinical Decision Support

Mercy, St. Louis: Automated Clinical Pathway for Heart Failure

Care standardization the target; bundled payment environment

Heart failure: mortality rate of 6%

Metrics targeted: HF<br> mortality, time to diuretic, reduce variable costs per case

Designed and optimized with analytics vendor platform based on Mercy data, practice, populations; driven from problem list, signs, and symptoms

Default orders—nursing: define daily diuresis goal; CDS-supported medication selection and dosing including Now dosing

1) HF = Heart failure.

Sources: HIMSS Enterprise Davies Award Recipients, http://www.himss.org/himss-enterprise-davies-award-recipients; Advisory Board research and analysis.
... and a Bad Case of Alert Fatigue

Example: ED$^1$ Sepsis Detection Alert at Anders Health System$^2$

With Alert Fatigue, Overrides and Frustrations Abound

![Graph showing volume of fired alerts]

6,000+ Alerts Fired Per Month
0.3% Alerts Followed

"They twisted their knee and I get a sepsis alert. It is no wonder these are ignored. They wear you out with alerts! Waste of time and fatigue the staff!!!"


1) ED = Emergency department.
2) Pseudonym.
©2018 Advisory Board • All Rights Reserved • advisory.com • 36516D
Technology is Delivering a Flood of New Data

Smartphones, and Genomes, and Sensors, Oh My!

A Sampling of New Data Sources

- Integrated Partners (e.g., social services, cross-continuum care)
- Remote Patient Monitoring (e.g., bedside monitors, remote patient monitoring, consumer wearables)
- Clinical Surveillance (e.g., public health, outbreak reports)
- Data from Outside Organizations (e.g., social)
- Environmental Data (e.g., IoT, RTLS, temperature, air quality)
- Genomes, Proteomes, Microbiomes, Metabolomes

Common Barriers to Adoption of New Sources

- Privacy / security concerns
- Immature technology
- Lack of budget
- Unclear benefit / ROI
- Staff already overwhelmed with data

Source: Health Care IT Advisor research and analysis.

1) IoT = Internet of things.
2) RTLS = Real-time locating system.
3) ROI = Return on investment.
Cognitive Overload and Clinician Burnout

Augmented Intelligence Reduces Cognitive Burden

Time Required vs. Number of Considerations for Decision Making

- Significant opportunity for AI and analytics
- Reliance on heuristics, rules of thumb, “good-enough”

“Medical thinking has become vastly more complex, mirroring changes in our patients, our health care system, and medical science. The complexity of medicine now exceeds the capacity of the human mind.”

Ziad Obermeyer, M.D. and Thomas Lee, M.D.

Sources: Millett D, Exclusive: “Three GPs a day seeking help for burnout, official data show,” GP, Jan 2018; Health Care IT Advisor research and analysis.

1. The Data Dilemma

2. AI and the New Machine Age

3. Who Watches The Machines?
AI: Are We There Yet?

And if Not, When?

We May Be at the Start of an Explosive Growth in AI Capabilities

Exponential Growth: AI rapidly gains capability and becomes a mainstream part of most digital systems.

Incremental Growth: AI continues to make small advances, delivering value in niche applications.

Unpredictable Timing: Some advances never seem to arrive (conversational systems), while others take off unexpectedly (smartphones).

AI Winters: AI has already gone through past phases of hype and troughs of disillusionment.

<table>
<thead>
<tr>
<th>50s</th>
<th>60s</th>
<th>70s</th>
<th>80s</th>
<th>90s</th>
<th>2000</th>
<th>2010</th>
<th>2020</th>
<th>2030</th>
<th>2040</th>
<th>2050</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Health Care IT Advisor research and analysis.
Novice to Superhuman in Just Four Hours

DeepMind’s AlphaZero Uses ‘Zero Human Knowledge’

By not using this human data, by not using human features or human expertise in any fashion, we’ve actually removed the constraints of human knowledge. **It’s able to therefore create knowledge for itself.**

David Silver, Lead Programmer

DeepMind’s AlphaZero

- AI product of Google subsidiary, DeepMind
- Provided no prior knowledge of the game; given only basic game rules and an objective (win)
- Learns through self-play at an accelerated pace (‘reinforced learning’); searches 80 thousand positions per second
- Variants of AlphaZero also defeated world champion Go and Shogi systems

AlphaZero outperformed chess world-champion, Stockfish,¹ in just 4 hours (300k steps)

---

¹ Stockfish is the 2016 Top Chess Engine Championship (TCEC) world-champion.

Sources: Vincent J, “DeepMind’s AI became a superhuman chess player in a few hours, just for fun,” The Verge, December 6, 2017; Gershgorn D, “DeepMind wants to find the next miracle material—experts just don’t know they’ll pull it off,” Quartz, October 25, 2017; Health Care IT Advisor research and analysis.
Need a Radiologist?

There’s an App for That

**Case in Brief: Stanford University**¹
**CheXNet Algorithm**

- Algorithm developed by researchers at Stanford University in the US can diagnose 14 common pathologies in chest x-rays
- Trained on ChestX-ray14, a public data set released by the NIH² containing 112,120 frontal-view chest x-ray images labelled with the 14 possible pathologies
- Outperforms previous models from the same data set for all 14 conditions and diagnoses pneumonia at an accuracy exceeding the performance of four control radiologists
- Produces heatmaps that visualize the areas of an image most indicative of disease

“I treat the model as a lazy resident. They’re not dumb, they’ll just use every trick they can find to avoid doing hard work.”

**Dr. Matthew Lungren, Radiologist**
Stanford University Medical Center

**Development of CheXNet**

Sept. 26, 2017
ChestX-ray14 data set released along with a preliminary algorithm that could detect the labelled conditions

≈ One week later
CheXNet could diagnose 10 of the 14 pathologies more accurately than all previous algorithms

≈ One month later
CheXNet surpassed best published results for all 14 pathologies and outperformed Stanford radiologists in detecting pneumonia


1) Stanford University Medical Center.
2) NIH = National Institutes of Health.

©2018 Advisory Board • All Rights Reserved • advisory.com • 36516D
Applicants Like You Liked This Job

Predictive Models Reduce Turnover, Improve Engagement

Case in Brief: MultiCare Health System

- Non-profit system based in Tacoma, WA with 16,000 employees
- Partnered with Arena, a cloud-based HR solution, to predict the likelihood that a candidate will be retained in a role
- Arena’s machine learning algorithms evaluate applicant submissions, digital interactions, and externally sourced data on the organization (e.g., employer review sites)
- Achieved a **40% reduction** in RN turnover at 180 days and a **28% reduction** in overall turnover at 180 days

Realized Benefits

- Reduced recruiting expenses
- More predictable staffing levels
- More experienced staff

MultiCare’s Hiring Process

Applicant completes a 15-20 minute assessment process on Arena’s platform

Algorithms predict the likelihood the applicant will be retained and engaged in the target role and send that information to the recruiter

Recruiters determine whether or not to send the candidate along to hiring managers

Hiring managers use Arena’s recommendation as an optional factor in the hiring decision

Source: Health Care IT Advisor research and analysis.
Differing Views on the Importance of Explainability

"The opaqueness of black-box models is really scary. When we can’t tell a clinician why a patient won’t do well on a certain medication, that can be a tough thing to blindly trust from a clinical perspective. We want to reach a place where we augment our practice through AI, rather than dictating.”

Mike Wall, PharmD, MBA
Chief Analytics Officer
The University of Chicago Medicine

"I am pushing to evaluate these models via a similar set of mechanisms as RCT\(^1\) or A/B testing. We should evaluate against the current status-quo and do a before/after study…We have to convince ourselves of the utility of these models. We should focus on utility before explainability.”

Nigam Shah, MBBS, PhD
Associate Professor of Medicine
(Biomedical Informatics)
Stanford University

Data → Black Box Model → Surgery is the best option (?)

1) RCT = Randomized controlled trial.

Source: Health Care IT Advisor research and analysis.
Accelerate Clinical Standardization

Improve Outcomes Through Embedded Decision Support

Case in Brief: Intermountain Healthcare

- 2,781-bed, 22-hospital system based in Salt Lake City, UT
- Long history of formal care process modeling and standardization, dating back to 1986
- Pneumonia protocol evaluates labs, vitals, and free text radiology reports in real time and can visually flag high-risk patients in the EHR
- Integrated, dynamic guidelines recommend an appropriate care setting, additional lab orders, and antibiotic selection based on risk and medical history

Predictive + Prescriptive Clinical Decision Support

1. The Data Dilemma

2. AI and the New Machine Age

3. Who Watches The Machines?
Driving the Decision Machine

Hint: The Analytics is Often the Easy Part

Begin with:
- Explicit leadership agreement on outcome goals, expected benefit mechanisms
- Participation from empowered representatives of impacted process
- External experience—learn from others

1. Acquire Data
   - The more the better, but...
   - High-quality, well-governed data pay enormous dividends
   - Diverse, cross-continuum sources improve predictions and robustness of models

2. Train or Refine the Model
   - Decide what features are important (e.g., explainability)
   - Apply practical and ethical constraints
   - Evaluate under realistic conditions (silent mode, real-time, incomplete data)

3. Redesign or Adapt Workflow
   - Embed insights directly into applications at key decision points
   - Reengineer processes as warranted
   - Consider the “5 rights” of decision support

4. Monitor Performance and Revisit
   - Ensure all models have a sponsor and regular evaluation against goals
   - All models require tune-ups as the environment changes.

Source: Health Care IT Advisor research and analysis.
Clinical Goal for Improvement:
1. Overall clinical goal: Decrease unnecessary/prolonged use of dexmedetomidine by implementing 48-hour automatic stop order
2. Objective of BPA: Notify MD, APP, RNs of automatic stop order at 48 hours to ensure that weaning and/or transition plan is created prior to expiration of order
3. Owner: Drug Utilization MGT:
4. Anticipated benefits: Safety: BPA intended to promote early transition planning to avoid unplanned/unanticipated discontinuation of therapy

Baseline:
1. Current state performance:
![Graph showing current state performance]

Problem:
1. Efforts: P&T-approved guidelines for appropriate dexmedetomidine use have been implemented. One of the restrictions is that use should not exceed 48 hours. Extensive communication and education have been provided to MDs, APPs, RNs, and PharmDs in all areas where dexmedetomidine is prescribed and administered.
2. Problem: The FDA-approved duration of therapy for dexmedetomidine is 24 hours. SHC’s use consistently exceeds this. Non-EPIC interventions have not been successful in decreasing duration of therapy as the average DOT per patient is 2.5-3 days. Primarily due to SHC culture, dexmedetomidine is typically being used as a 1st line agent for sedation, regardless of expected duration of sedation. Culture is difficult to change without some hard-coded support.
3. Urgency: Go-live for the BPA was determined to be Monday, March 13 at the Drug Utilization MGT based on timeline estimates obtained by EPIC. Education and messaging to all stakeholders has been completed and all are prepared for this go-live. It would be a lot of confusion and re-work to have to postpone/delay this. Additionally, this is a significant piece of the overall dexmedetomidine cost savings initiative with an estimated $2.5M impact to the organization.

Alert Language and Structure:
1. Target audience: Inpatient, ED RNs and MDs
2. Trigger event: Opening chart
3. Alert Criteria: Patients with active dexmedetomidine orders that started 24 and 36 hrs. ago.
4. Message:
   • MD/APP:
     • 24 hr BPA: “You have 24 hours remaining until the dexmedetomidine order will automatically be discontinued. Consider weaning or transition to another agent now.”
     • 36 hr BPA: “You have 12 hours remaining until the dexmedetomidine order will automatically be discontinued. If not already started, begin to wean or to transition to an alternative agent if sedation is still required.”
   • Nurses:
     • 24 hr BPA: “You have 24 hours remaining until the dexmedetomidine order will automatically be discontinued. Please discuss with the primary team.”
     • 36 hr BPA: “You have 12 hours remaining until the dexmedetomidine order will automatically be discontinued. Contact the MD to plan for weaning or transitioning to an alternative agent.”

User Action: Acknowledgement
Reference link: Lexicomp (Guidelines pending post to intranet)

Sustain Results:
1. Ongoing/future interventions: Weekly metrics are posted in D1, E2, E29 for visibility into utilization & sustainability of progress.
2. Metrics and targets: 75% decrease in utilization when compared to FY16
3. Possible unintended consequences: None
4. Revision / removal owner:

Next Steps:
1. When the above is completed to the best of your ability, please submit email as an attachment to the SHC HelpDesk at shcservicedesk@accenture.com
2. An informaticist will contact you to review details and prepare for presentation to the Clinical Decision Support Committee within 2 weeks; you are strongly encouraged to attend or send a delegate
Who Watches the Machines?

“To Err Is Human, To Really Foul Things Up Requires a Computer”

Automated processes need human oversight
Governance is focused on quantifiable target outcomes
Periodically evaluate processes against goals
“Circuit breaker” rules to limit potential harm

Algorithms Gone Wild

Unique Challenges to AI in Health Care

**Business Challenges**

- **Complexity**: Medical issues do not appear in isolation and coordination of care is difficult.
- **Threat to Human Jobs**: Strong fear associated with technology displacing human workers.
- **Cost**: The high costs for developing, testing, certifying, and implementing can be a barrier.
- **Workflow**: How do AI solutions fit into existing workflows? How much effort is required to use it? Does it interfere or annoy unnecessarily?
- **Competing Priorities**: We are still in the midst of installing basic and foundational systems (e.g., EMRs) while addressing regulatory and other pressing PHM initiatives.

**Legal and Ethical Challenges**

- **Regulation**: Health IT regulations are hotly debated at the national level. Finding the right balance of public health protection and fostering innovation are key.
- **Legal**: Juries still award large sums when health care is not applied properly or expected outcomes are not achieved.
- **Liability**: How do we deal with computer failings? Even if AI approaches are statistically better, there may be liability when it fails.
- **Human Touch**: How will we interact with AI? How strongly will we require the human touch and human compassion in health care?
Health Care IT Advisor

Research Director
Greg Kuhnen
kuhneng@advisory.com

Research Team
Jacqueline Beltejar
Bethany Jones
Nouran Ragaban
Sophie Ranen
Andrew Rebhan

Program Leadership
Jim Adams

Design Consultant
Kevin Matovich

LEGAL CAVEAT
Advisory Board is a division of The Advisory Board Company. Advisory Board has made efforts to verify the accuracy of the information it provides to members. This report relies on data obtained from many sources, however, and Advisory Board cannot guarantee the accuracy of the information provided or any analysis based thereon. In addition, Advisory Board is not in the business of giving legal, medical, accounting, or other professional advice, and its reports should not be construed as professional advice. In particular, members should not rely on any legal commentary in this report as a basis for action, or assume that any tactics described herein would be permitted by applicable law or appropriate for a given member’s situation. Members are advised to consult with appropriate professionals concerning legal, medical, tax, or accounting issues, before implementing any of these tactics. Neither Advisory Board nor its officers, directors, trustees, employees, and agents shall be liable for any claims, liabilities, or expenses relating to (a) any errors or omissions in this report, whether caused by Advisory Board or any of its employees or agents, or sources or other third parties, (b) any recommendation or graded ranking by Advisory Board, or (c) failure of member and its employees and agents to abide by the terms set forth herein.

The Advisory Board Company and the “A” logo are registered trademarks of The Advisory Board Company in the United States and other countries. Members are not permitted to use these trademarks, or any other trademark, product name, service name, trade name, and logo of Advisory Board without prior written consent of Advisory Board. All other trademarks, product names, service names, trade names, and logos used within these pages are the property of their respective holders. Use of other company trademarks, product names, service names, trade names, and logos or images of the same does not necessarily constitute (a) an endorsement by such company of Advisory Board and its products and services, or (b) an endorsement of the company or its products or services by Advisory Board. Advisory Board is not affiliated with any such company.

IMPORTANT: Please read the following.
Advisory Board has prepared this report for the exclusive use of its members. Each member acknowledges and agrees that this report and the information contained herein (collectively, the “Report”) are confidential and proprietary to Advisory Board. By accepting delivery of this Report, each member agrees to abide by the terms as stated herein, including the following:

1. Advisory Board owns all right, title, and interest in and to this Report. Except as stated herein, no right, license, permission, or interest of any kind in this Report is intended to be given, transferred to, or acquired by a member. Each member is authorized to use this Report only to the extent expressly authorized herein.

2. Each member shall not sell, license, republish, or post online or otherwise this Report, in part or in whole. Each member shall not disseminate or permit the use of, and shall take reasonable precautions to prevent such dissemination or use of, this Report by (a) any of its employees and agents (except as stated below), or (b) any third party.

3. Each member may make this Report available solely to those of its employees and agents who (a) are registered for the workshop or membership program of which this Report is a part, (b) require access to this Report in order to learn from the information described herein, and (c) agree not to disclose this Report to other employees or agents or any third party. Each member shall use, and shall ensure that its employees and agents use, this Report for its internal use only. Each member may make a limited number of copies, solely as adequate for use by its employees and agents in accordance with the terms herein.

4. Each member shall not remove from this Report any confidential markings, copyright notices, and/or other similar indicia herein.

5. Each member is responsible for any breach of its obligations as stated herein by any of its employees or agents.

6. If a member is unwilling to abide by any of the foregoing obligations, then such member shall promptly return this Report and all copies thereof to Advisory Board.